Minerva Neurosciences Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences or view top-rated stocks.

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences, Inc. (NASDAQ:NERV) announced its quarterly earnings results on Monday, August, 2nd. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.08.
View Minerva Neurosciences' earnings history.

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have decreased by 71.1% and is now trading at $1.84.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 1 year target prices for Minerva Neurosciences' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Minerva Neurosciences' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 253.3% from the stock's current price.
View analysts' price targets for Minerva Neurosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Minerva Neurosciences include KemPharm (KMPH), Citius Pharmaceuticals (CTXR), Infinity Pharmaceuticals (INFI), TherapeuticsMD (TXMD), Millendo Therapeutics (MLND), Taiwan Liposome (TLC), Nature's Sunshine Products (NATR), Inozyme Pharma (INZY), Puma Biotechnology (PBYI), CTI BioPharma (CTIC), Sernova (SEOVF), DURECT (DRRX), Vincerx Pharma (VINC), Wave Life Sciences (WVE) and Theratechnologies (THERF).
View all of NERV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.59%), Millennium Management LLC (3.03%), Dimensional Fund Advisors LP (2.50%), Renaissance Technologies LLC (2.35%), Morgan Stanley (1.48%) and Morgan Stanley (1.48%). Company insiders that own Minerva Neurosciences stock include Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Vanguard Group Inc., Northern Trust Corp, Morgan Stanley, Morgan Stanley, Geode Capital Management LLC, and Bridgeway Capital Management LLC. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences or view top insider-selling stocks.

NERV stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, GSA Capital Partners LLP, Ergoteles LLC, Tibra Equities Europe Ltd, Jump Financial LLC, XTX Topco Ltd, and LMR Partners LLP.
View insider buying and selling activity for Minerva Neurosciences or or view top insider-buying stocks.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NERV stock can currently be purchased for approximately $1.84.

Minerva Neurosciences has a market capitalization of $78.61 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $1.94 million in net income (profit) each year or $0.05 on an earnings per share basis.

Minerva Neurosciences employs 11 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences is headquartered at 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at [email protected]